Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerzeparib Phase I in Advanced Solid Tumors
NCT05021367Phase 1Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lerzeparib in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicities at 28 days and Maximum tolerated dose at 28 days. Started Sep 2021; status: active, not recruiting.
02
Drugs
lerzeparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05021367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05021367.